Sale fever for research of the drug and the business becomes a millionaire. While the H1N1 virus terrorises the world, someone loses an opportunity to cash out. The turnover of the influence is worth 10 billion dollars for pharmaceutical companies who loses, who gains?
Sale fever for research of the drug and the business becomes a millionaire. While the H1N1 virus scares the world, someone loses an opportunity to cash out. The turnover of the influence is worth 10 billion dollars for pharmaceutical companies such as Big Pharma, called in haste to prepare the antidote. Although each individual dose of vaccine is likely to cost ten euro, in fact, is the volume of sales to make the mass.
According to calculations by JP Morgan on the governments of various countries have already booked at the 3-4 companies that produce the vaccine on a large scale, at least 600 million doses, for a 3 billion euro, about 4 , $ 3 billion. In recent days, has been joined by France, with an order for 94 million doses and a check for 1 billion euro. The list is intended to grow.
JP Morgan: 7 billion people!
estimate that, eventually, to 600 million doses already booked if they add up another 350 million for an additional bill of over 2 and a half billion dollars, more than 1.8 billion euro. In fact, Big Pharma is a business without fail. The book doses billion, or via the reservation, is largely insufficient to meet a world population of nearly 7 billion people. But it is also more or less, the maximum that the current systems can produce the form of injectable ampoules (in Europe) or a nasal spray (U.S.). There will be no inventory .
The protagonists: GlaxoSmithKline Sanofi Aventis, Novartis, Astra Zeneca
giants of the pharmaceutical industry players in the billion-dollar business are the usual suspects, from GlaxoSmithKline Sanofi Aventis, passing by Novartis, Astra Zeneca. Not only
vaccines though. In addition to the flu because there are medicines for people, the flu has already taken. Again, it is Big Pharma to dominate the market. First of all, with Roche's Tamiflu. And then with Relenza, even GlazoSmithKline. According to JP Morgan, Tamiflu and Relenza will, respectively, Roche and Glaxo, sales of $ 1.8 billion in rich countries, more than 1.2 billions of dollars in developing countries. In total, some $ 3 billion, over 2 billion euro. Between vaccines and medicines, the risk of pandemic is to Big Pharma, about 10 billion dollars.
The vaccine business
A relatively new business that the vaccines that originally did not seem too convincing multinational pharmaceutical companies, we get less than the ordinary sale of a drug. Wyeth was the pioneer in the field with a pneumococcal vaccine (84 dollars per dose), followed by Merck with one against the human papilloma (130 U.S. dollars per dose). At this point, Big Pharma has discovered the field to start the big pharmaceutical Risk: Novartis bought Chiron, Sanofi Aventis took Pasteur, MedImmune Astra Zeneca, Glaxo ID Biomedical, yet the Acambis Sanofi, Pfizer, Wyeth has absorbed. A concentration of resources and considerable research.
